Figure 1

Adjusted splines of baseline homocysteine, folate and vitamin B12 and renal outcome.

The solid line represents the spline of baseline homocysteine (A) folate (B) and vitamin B12 (C) and incident chronic kidney disease adjusted by age, gender, systolic blood pressure, diabetes, smoking, cholesterol, HDL-C, triglycerides, body mass index, estimated glomerular filtration rate (eGFR) and previous use of ACEIs/ARBs. Adjusted splines of baseline homocysteine (D), folate (E) vitamin B12 (F) and eGFR decline rate are also shown. Dotted lines represent the 95% confidence interval of the splines. Incident chronic kidney disease was defined as follow-up eGFR <60 ml/min/1.73 m² and eGFR decline rate >1 ml/min/1.73 m²/year. eGFR decline rate was calculated as the difference between the follow-up eGFR and baseline eGFR, which was divided by follow-up duration and expressed as ml/min/per 1.73 m²/year. Negative eGFR change indicates a fall in eGFR during follow-up. Abbreviations: ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol.